Functional Role of G9a Histone Methyltransferase in Cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Post-translational modifications of DNA and histones are epigenetic mechanisms, which affect the chromatin structure, ultimately leading to gene expression changes. A number of different epigenetic enzymes are actively involved in the addition or the removal of various covalent modifications, which include acetylation, methylation, phosphorylation, ubiquitination, and sumoylation. Deregulation of these processes is a hallmark of cancer. For instance, G9a, a histone methyltransferase responsible for histone H3 lysine 9 (H3K9) mono- and dimethylation, has been observed to be upregulated in different types of cancer and its overexpression has been associated with poor prognosis. Key roles played by these enzymes in various diseases have led to the hypothesis that these molecules represent valuable targets for future therapies. Several small molecule inhibitors have been developed to specifically block the epigenetic activity of these enzymes, representing promising therapeutic tools in the treatment of human malignancies, such as cancer. In this review, the role of one of these epigenetic enzymes, G9a, is discussed, focusing on its functional role in regulating gene expression as well as its implications in cancer initiation and progression. We also discuss important findings from recent studies using epigenetic inhibitors in cell systems in vitro as well as experimental tumor growth and metastasis assays in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756 · cited 1×
“These modifications regulate the ability of transcription factors to access the underlying DNA by modifying histone affinity for its negatively charged sugar backbone, representing a fundamental regulatory mechanism, which is able to impact transcription (Figure 1), replication, and chromatin stability (7, 8).”
BackgroundmTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
High-Resolution Profiling of Histone Methylations in the Human Genome
Barski, A., Cuddapah, S., Cui, K., Roh, T.-Y., Schones, D. E., Wang, Z., Wei, G., Chepelev, I., & Zhao, K. (2007) · Cell · doi:10.1016/j.cell.2007.05.009 · Cited by 6,845 · cited 2×
“For instance, while H3K9 di- and trimethylation are transcriptional repressive marks, H3K9 mono-methylation has been observed to characterize active promoters (25).”
BackgroundRegulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012 · cited 1×
“Following this evidence, it is thought that the particular combination of N-terminal modifications results in specific signals which the cell is able to interpret as a readable code, known as the “histone code” (43, 44).”
BackgroundHistone demethylation mediated by the nuclear amine oxidase homolog LSD1
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., Casero, R. A., & Shi, Y. (2004) · Cell · doi:10.1016/j.cell.2004.12.012 · Cited by 4,051
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins
Lachner, M., O'Carroll, D., Rea, S., Mechtler, K., & Jenuwein, T. (2001) · Nature · doi:10.1038/35065132 · Cited by 2,868 · cited 1×
“The complex is responsible for methylating H3K9, a mark which is recognized by the heterochromatin protein 1 (HP1), leading to transcriptional silencing (52).”
BackgroundRegulation of chromatin structure by site-specific histone H3 methyltransferases
Rea, S., Eisenhaber, F., O'Carroll, D., Strahl, B. D., Sun, Z.-W., Schmid, M., Opravil, S., Mechtler, K., Ponting, C. P., Allis, C. D., et al. (2000) · Nature · doi:10.1038/35020506 · Cited by 2,845 · cited 2×
“The fact that gene expression was regulated by methylation has been known previously; the discovery of HMT, SUV39H1, has facilitated the understanding of histone methylation and gene expression (33, 34).”
BackgroundActive Genes Are Tri-Methylated at K4 of Histone H3
Santos-Rosa, H., Schneider, R., Bannister, A. J., Sherriff, J., Bernstein, B. E., Emre, N. C. T., Schreiber, S. L., Mellor, J., & Kouzarides, T. (2002) · Nature · doi:10.1038/nature01080 · Cited by 2,138 · cited 1×
“Methylation at different histone residues are associated with either repressive or active chromatin states (36).”
BackgroundWADDINGTON, C. H. (1968) · Nature · doi:10.1038/218525a0 · Cited by 1,061
MDC1 is a mediator of the mammalian DNA damage checkpoint
Stewart, G. S., Wang, B., Bignell, C. R., Taylor, A. M. R., & Elledge, S. J. (2003) · Nature · doi:10.1038/nature01446 · Cited by 874
Reversal of H3K9me2 by a Small-Molecule Inhibitor for the G9a Histone Methyltransferase
Kubicek, S., O'Sullivan, R. J., August, E. M., Hickey, E. R., Zhang, Q., Teodoro, M. L., Rea, S., Mechtler, K., Kowalski, J. A., Homon, C. A., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.01.017 · Cited by 859
Henry, K. W., Wyce, A., Lo, W.-S., Duggan, L. J., Emre, N. C. T., Kao, C.-F., Pillus, L., Shilatifard, A., Osley, M. A., & Berger, S. L. (2003) · Genes & Development · doi:10.1101/gad.1144003 · Cited by 714 · cited 1×
“Cross-talk between ubiquitination and methylation has been observed, suggesting that ubiquitination and deubiquitination-related effects are mainly mediated by influencing the histone methylation status (20).”
BackgroundSchenk, T., Chen, W. C., Göllner, S., Howell, L., Jin, L., Hebestreit, K., Klein, H.-U., Popescu, A. C., Burnett, A., Mills, K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2661 · Cited by 672 · cited 2×
“KDM2/7 Daminozide (107), TC-E 5002 (108) JMJD2A DMOG (109) KDM6B and KDM6A combined GSK-J1/J4 (110) JMJC family IOX1 (111) JMJD2 ML324 (112) LSD1 PCPA (phenylcyclopropylamine) (113) Novel histone demethylase LSD1 inhibitors RN-1 (113), TCP (114), CAS 927019- 63-4 (115), CBB1007 (116), S2101 (116) Jumonji family JIB-04…”
G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis
Feldman, N., Gerson, A., Fang, J., Li, E., Zhang, Y., Shinkai, Y., Cedar, H., & Bergman, Y. (2006) · Nature Cell Biology · doi:10.1038/ncb1353 · Cited by 651
Chen, M.-W., Hua, K.-T., Kao, H.-J., Chi, C.-C., Wei, L.-H., Johansson, G., Shiah, S.-G., Chen, P.-S., Jeng, Y.-M., Cheng, T.-Y., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0833 · Cited by 369 · cited 5×
“Higher G9a expression levels were also noted to be associated with poor prognosis (2, 65, 74, 79).”
BackgroundInfluentialRyu, H., Smith, K., Camelo, S. I., Carreras, I., Lee, J., Iglesias, A. H., Dangond, F., Cormier, K. A., Cudkowicz, M. E., H. Brown, R., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03077.x · Cited by 353
Self-citationProtein lysine methyltransferase G9a acts on non-histone targets
Rathert, P., Dhayalan, A., Murakami, M., Zhang, X., Tamas, R., Jurkowska, R., Komatsu, Y., Shinkai, Y., Cheng, X., & Jeltsch, A. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.88 · Cited by 347 · cited 1×
“There are several other proteins identified to be G9a targets including CDYL1, WIZ, and ACINUS (67).”
Background
Cited by
Writing, erasing and reading histone lysine methylations
Hyun, K., Jeon, J., Park, K., & Kim, J. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.11 · Cited by 1,250
The emerging role of epigenetic therapeutics in immuno-oncology
Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433
Kim, T. W., Lee, S. Y., Kim, M., Cheon, C., & Ko, S.-G. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0930-1 · Cited by 304
Bárcena‐Varela, M., Caruso, S., Llerena, S., Álvarez‐Sola, G., Uriarte, I., Latasa, M. U., Urtasun, R., Rebouissou, S., Alvarez, L., Jimenez, M., et al. (2019) · Hepatology · doi:10.1002/hep.30168 · Cited by 130
“(16) G9a expression is dysregulated in cancer, contributing to cell growth, survival, adaptation to hypoxia, and metastasis.(15) Very recently, G9a was shown to be up-regulated and to promote HCC progression.”
BackgroundSaha, N., & Muntean, A. G. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188498 · Cited by 56
Metadata
- Authors
- Casciello, F., Windloch, K., Gannon, F., & Lee, J. S.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2015-09-25
- Volume
- 6
- Pages
- 487-487
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W1920711459
- Cited by
- 246
- References
- 20
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.